walgreen report result expect guidanc shave
reflect manag conservat
updat forecast estim oct
busi strategi outlook
found walgreen boot allianc lead
pharmaci retail leverag scale provid conveni
current compani gener nearli billion revenu
dispens billion prescript annual repres
quarter drug market domest store
strateg locat high traffic area gener
million per store drive scale help enabl compani
negoti effect supplier scale remain critic
increasingli competit market wit
ration subscal peer core busi center
around pharmaci account nearli three fourth
revenu main driver traffic manag need
pull volum recent acquir rite aid
locat along store abroad reimburs stabil
manag focus leverag scale foster
strateg partnership increas traffic cross sell
opportun long term focu improv coordin care
histor compani strategi base footprint
expans establish scalabl infrastructur
focu evolv concentr shift improv
store util strateg align healthcar partner
address macro trend local commun healthcar
incur oper capit invest
success complet numer clinic cpg trial
success roll initi incorpor
guidanc serv off-set continu
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
oper locat state
countri core defens posit primarili around
pharmaci place high traffic locat current compani
largest retail pharmaci market share around exclud mail
provid signific cost advantag scale annual
compani gener billion revenu consist retail
pharmaci around pharmaci around
pharmaceut wholesal around establish strateg
partnership offer increment servic increas averag revenu per
custom equiti stake
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
walgreen report result expect guidanc
shave reflect manag conservat oct
quarter result sever put take overal
figur larg line consensu expect
report capitaliq slightli shi model despit
prescript volum strength acceler share
repurchas volum adjust ep declin year
increas mix shift toward central pharmaci
increas oper expens growth initi
manag make necessari invest
improv store util off-set neg reimburs
trend near term better posit compani
wholist provid maintain narrow moat
lower fair valu estim per share
reflect slower-than-expect realiz initi
larg hinder
fourth quarter revenu grew year year
constant currenc basi billion
retail pharmaci sale increas intern
sale declin larg due continu currenc
headwind basi point store optim
initi includ closur net store
result declin market share
adjust prescript increas year
year front-end sale decreas year year
declin same-stor sale compstore basi think
compstore stabil target health
well promot activ roll kroger
partnership gener merchandis strong central fill
growth neg affect overal adjust
margin lower overal oper margin
somewhat mitig acceler share buy-back
result normal ep better
consensu estim shi expect
manag continu repurchas share drive
share count year year compani
dividend yield
manag provid flat fiscal ep larg due
increas reimburs pressur upcom
renew signific number payor contract
million million invest growth initi
adjust continu currenc headwind fiscal
ep guidanc compar investor
conserv reflect fulli load initi
invest correspond benefit
possibl sign partnership negoti take
longer initi expect longer term believ
partnership enabl compani offer
wholist care compliment digit expand
lower fair valu estim per
share reflect slower-than-expect
benefit cost save initi current
reimburs environ impact forecast
assumpt continu reimburs pressur
public privat third parti payor increas shift mix
toward day prescript medicar part
continu growth specialti drug like weigh
overal profit initi like improv
effici fiscal strateg initi
includ forecast like materi
fiscal
multipl time free cash flow yield
forecast base core assumpt legaci
front end revenu legaci busi rite
aid store sinc figur discret provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
make progress cost save initi
bull-cas fair valu estim per share
scenario abl grow domest retail pharmaci
pace industri spend project nearli
also grow wholesal inflationari rate
scenario oper margin anticip improv
rel base case basi point annual
reimburs materi impact near
term off-set implement cost save
initi
gener strateg initi
forecast base
assumpt
triangul report figur morningstar
estim arriv volum price driver
assumpt includ split specialti legaci
pharmaceut base indic fiscal
specialti revenu north billion
estim legaci pharmaci busi grown
inflationari base case assum specialti drug
grow mid-double-digit annual discret
uncertainti rate stand medium due
increas competit environ execut risk
strateg initi addit potenti regulatori
chang associ increas price transpar
part valuat framework addit
base-cas dcf also model bull bear case
valuat scenario critic debat
surround compani abil better util store
strateg initi off-set reimburs
pressur addit manag need pull
increment volum acquir store
bear-cas fair estim per share
scenario revenu declin fiscal grow
inflationari rate discret forecast due
continu deterior domest intern
reimburs result oper profit estim
basi point base case
walgreen boot allianc assign narrow moat
rate cost advantag
establish signific scale enabl
foster meaning partnership negoti
power supplier differenti abil
gener signific volum conveni locat
across nation firm dispens billion adjust
prescript annual account nearli three quarter
overal sale
approxim million revenu
foot notabl better sale per store closest
peer million doubl pharmaci
averag million abil drive increment
volum averag store like driven
conveni orient concept help best
locat regularli updat store coupl macro
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
trend includ prefer age popul
purchas prescript physic
locat
de-emphasize mail order pharmaci scale allow
compani leverag fix cost pharmacist rent
effect sub-scal peer contribut
declin market share smaller
pharmaci deterior third largest competitor
strateg partnership conscious
share price inform improv transpar drive
traffic negoti payor
opportun key partnership serv differ purpos
includ distribut
healthcar payor optum pbm
specif exampl favor distribut term
contract contract extend
includ day payment doubl
market norm day day closest peer
enabl compani optim work capit
account third abc revenu
charg averag fee basi point versu basi
point closest peer note drug channel
compar report ebit margin
includ increas inventori threshold direct deliveri
retail locat shift inventori
distributor reduc need maintain central
distribut center significantli lower overhead
expens arrang also supplement
synergi wbad swiss gener purchas joint
ventur
custom combin wbad
prime recent acquisit rite aid store manag
roughli third gener drug volum help
price negoti sourc stake
convers warrant equiti
scale also provid abil establish strateg
partnership enhanc store traffic one partnership
prime llc form alliancerx
third-largest specialti provid arrang
compliment focu limit distribut drug ldd
specialti drug key driver overal drug spend
signific compon fda drug approv
partnership sizabl specialti contract
cross shield feder employe program away
incumb contract estim billion
result estim gener annual
specialti revenu billion repres nearli
third specialti market
compani also conduct partnership trial
cost reflect oper result none
benefit includ futur period
key partnership includ lab corp
strong price leverag cpg item abil
obtain price could improv cross sell
front end product result improv profit
trial recent complet kentucki market
grocer lead market share manag roll
similar store store concept other
ancillari servic lab imag primari care clinic
variou clinic servic audiolog optic
improv util stock space longer
need direct store deliveri
initi like foster increas foot traffic
object recent announc partnership
advoc healthcar offer primari care
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
neg drag profit beauti well
account approxim front end sale
continu partial off-set declin cpg retail sale
longer term object would increas penetr
brand product boot increas
gross margin front end sale similar level current
achiev europ nearli doubl gross
margin
addit benefit declin
pharmaci market share mass merchant grocer
smaller nation chain grown
market share last sever year support
posit scale critic maintain competit
posit retail pharmaci
lastli consid one valu tenant
landlord reit compani signific
negoti leverag especi import
leas locat mani year term
leas need renew near term view
negoti rate like benefit base
sensit market rate fulli load retail rental rate
feet estim dollar negoti
favor would benefit compani million
annual believ figur
incorpor guidanc may possibl come
play long term cost save initi
compani scale instrument steadili
grow quarterli market share novemb
februari support doubl digit return
believ underli moat sourc attribut
weaken time due increas reimburs
pressur public privat third parti payor
increas on-line competit despit implement
intern strateg initi overal return like
short histor norm prior dip
cost capit fiscal
integr allianc boot acquisit
lawsuit around fail therano partnership sinc
legal settlement senior execut
replac expect minor continu margin
expans issu continu fade
cpg compon roughli half front end retail sale
roughli overal sale declin
consecut quarter increas price competit
commod product mass merchant on-line
retail declin partial self-inflict
manag conscious ration unprofit
front-end sku last quarter longer caus
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
largest retail pharmaci vast network
abl reach consum
provid scale cost advantag
ostrateg partnership focus increas store
util clinic partner local commun
healthcar natur extens provid
coordin care increas sticki
oth kroger initi improv cpg price
critic step enabl increas
perform front end oper
oth confluenc reimburs price pressur
increas shift mix toward day prescript
medicar part specialti drug declin
cpg neg impact profit
ohealthcar reform recent controversi price
transpar like increas stock volatil
could pose fundament threat
oth firm face increas price competit
mass merchant internet retail consum
commod product neg impact
front end growth profit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
fiscal compani nearli billion cash
equival off-set billion debt
debt/capit ratio fiscal gross leverag
portion cash balanc use acquisit
approxim store appear
firm need issu new debt believ
firm abl rebuild cash balanc
normal cours busi free cash flow gener
billion fiscal transact
expect level return normal level billion
annual common stock dividend averag
billion last coupl year forward yield
repurchas billion worth
stock last coupl year manag
indic plan repurchas million worth
balanc fiscal year longer term manag
expect purchas roughli billion annual
oper matur competit market signific
share main risk associ reimburs
pressur public privat third parti payor
increas shift mix toward day prescript
medicar part increas cost procur
pharmaceut signific chang feder
state drug regul compani signific
market share entri new competitor would like
unlik signific chang economi
market dynam could pose risk decreas
util drug either driven slower new drug
fewer altern gener option
formulari constraint
manag abil leverag signific fix cost
maintain store high rent staf
pharmacist may also
impact
pbm would
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
consolid healthcar compani provid
could influenc prescript fill
intern oper face risk
associ reimburs mix cost procur
competit posit entri new competitor
decreas util risk would vari
base countri compani oper
oper intern countri lastli signific
currenc could neg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
stewardship rate overal leader season
divers consum background see
stefano pessina firm largest sharehold
ceo execut vice chairman sinc januari
posit undoubtedli given iron grip
firm perspect everi aspect
oper strategi driven pessina larg
view mani current sharehold compet
retail given earlier turnaround allianc boot
busi believ extens success
histori oper europ largest retail pharmaci
believ new manag team led stefano
foster strateg partnership add posit
walgreen
partnership lab corp prime
compani scale mani effici also
roll acquisit rite aid store
significantli lower throughput product
ceo/director/vic chairman
repres date owner name posit common share held report holder issuer
fidel manag research compani
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
walgreen report result expect guidanc
shave reflect manag conservat oct
quarter result sever put take overal
figur larg line consensu expect
report capitaliq slightli shi model despit
prescript volum strength acceler share
repurchas volum adjust ep declin year
increas mix shift toward central pharmaci
increas oper expens growth initi
manag make necessari invest
improv store util off-set neg reimburs
trend near term better posit compani
wholist provid maintain narrow moat
lower fair valu estim per share
reflect slower-than-expect realiz initi
larg hinder
fourth quarter revenu grew year year
constant currenc basi billion
retail pharmaci sale increas intern
sale declin larg due continu currenc
headwind basi point store optim
initi includ closur net store
result declin market share
adjust prescript increas year
year front-end sale decreas year year
declin same-stor sale compstore basi think
compstore stabil target health
well promot activ roll kroger
partnership gener merchandis strong central fill
growth neg affect overal adjust
margin lower overal oper margin
somewhat mitig acceler share buy-back
result normal ep better
consensu estim shi expect
manag continu repurchas share drive
share count year year compani
dividend yield
manag provid flat fiscal ep larg due
increas reimburs pressur upcom
renew signific number payor contract
million million invest growth initi
adjust continu currenc headwind fiscal
ep guidanc compar investor
conserv reflect fulli load initi
invest correspond benefit
possibl sign partnership negoti take
longer initi expect longer term believ
partnership enabl compani offer
wholist care compliment digit expand
settlement bellweth feder trial
provid much-need relief teva oct
instead kick much-await feder opioid trial
oct would influenc outcom
case million settlement four
five defend three distributor teva
two ohio counti affect opioid epidem
cuyahoga summit announc court
initi teva term disclos includ
cash payment million donat
million opioid treatment medic three-year
period understand teva also settl principl
north carolina pennsylvania tennesse texa
increment inform forthcom although
guidanc provid extrapol
announc payment tent settlement provid
investor relief sinc market price
financ crunch settlement meaning step
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
toward global settlement remov teva
defend track litig schedul proceed
earli share close nearli news
landmark settlement ahead feder court kickoff
surpris public pharmaceut compani take
step distanc highli charg
polit matter remov largest overhang
share due time constraint move piec
initi settlement probabl came premium
continu believ increment settlement
requir up-front payment rather spread
multipl year manag compani
cover revisit sensit fair valu estim
figur releas maintain no-moat
high uncertainti rate fair valu estim teva
pleas see aug oct note background
decade-old opioid content pharmaceut
month suspens wall street journal report
settlement involv payment billion three
major pharmaceut distributor time
period although term defend particip
appear fluid landmark settlement ahead
oct feder court kick surpris public
pharmaceut suppli compani want distanc
highli charg polit matter
remov largest overhang respect share
summar aug note decade-old
content pharmaceut suppli chain
culmin standoff ohio feder court
lawsuit repres state citi
counti accus drug manufactur activ market
addict drug pharmaceut distributor fail
detect/report suspici opioid order mani
defend case gener drug manufactur
pharmaceut distributor retail pharmaci
coverag drug manufactur spend signific dollar
market brand drug like crux civil
case unlik brand drug gener significantli
cheaper formul sold base price
activ market result think gener
manufactur face lower penalti settl
rel smaller amount brand opioid
indic previous believ settlement
would requir up-front payment dollar services/
product rather could spread multipl year
think make potenti settlement
manag compani coverag
factor smaller payment shorter time period
may modestli adjust fair valu estim revisit
sensit firm settlement figur releas
howev expect impact on-going oper
moat rate
opioid litig overhang continu exert pain
drug manufactur distributor aug
across thousand civil case mostli
state court repres state prosecutor
compens famili hurt opioid
epidem plaintiff case accus drug
manufactur activ market addict drug
pharmaceut distributor fail detect/report
suspici opioid order mani defend
case gener drug manufactur pharmaceut
distributor retail pharmaci coverag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
three pharmaceut distributor coverag
handl roughli drug dispens across
countri sophist infrastructur allow
track manag suppli logist drug
result key role distributor track drug
provid copi drug order drug enforc
administr histor role requir
polic opioid civil suit distributor
accus market profit distribut
opioid prosecut team alleg distributor
alert suspici spike opioid
volum step requir report
walgreen includ group compani
gener sourc joint ventur quarter
equiti stake
consider specul distributor activ
discuss prosecutor propos financi
settlement rang billion
distributor distributor like abl absorb
propos fine long spread multipl
first opioid case settl purdu
agre justic depart fine million
intens market push brand opioid drug
oxycontin subsequ purdu also settl
state washington charg over-
prescript oxycontin year
least eight state feder opioid settlement
defend agre pay larg fine
million
purdu million case settl aggreg
nearli billion span
recent financi demand acceler
fuel polit social activist advoc
compani compens famili impact opioid
crisi recent civil case settlement sum
loom billion local oklahoma court
purdu teva reach court settlement
million million respect aug
oklahoma judg rule johnson johnson fine
million compani plan appeal feder
court result abus discret local
oklahoma judg elect offici understand
purdu teva settl court avoid
potenti neg sway onto significantli larger feder
case pend ohio hit hardest addit
oklahoma case two gener drug manufactur
defens endo allergan settl ohio million
million respect reckitt benckis also agre
settl govern billion
billion cumul settlement
settl decid opioid case financi
crippl defend includ legal fee
mount defens instanc estim
unlik prior civil case feder court ohio
propos consolid roughli civil case
across multipl district approxim
opioid case countri trial schedul kick
oct consider leak propos term
suggest activ settlement negoti
play continu exert signific pressur relev
healthcar stock like impetu settl
consolid case eerili similar landmark
multi district litig mdl creat
relat civil person injuri wrong
death case asbesto manufactur notabl john
manvil mdl case tri en mass behalf
plaintiff similarli situat feder level
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
due larg number parti involv civil trial
schedul occur multipl track overal
defend anticip feder court neutral
venu rel local court run judg
special interest collect largest fine
drug manufactur distributor improv re-elect
aspir although activ negoti ohio behind
close door unidentifi sourc indic
purdu may explor unpreced
billion settlement decept market well-
known opioid painkil oxycontin purdu case
front center activ market brand opioid
aggreg revenu billion
asbesto mdl defend file bankruptci
protect strategi purdu may may
mani defend opioid litig
attent event transpir ohio prepar
respect defens base figur present
drug enforc administr purdu pharma
manufactur opioid pill
unlik larger peer compani activ market
brand drug teva manufactur opioid
pill distribut throughout countri time
period actavi pharma compani teva acquir
manufactur opioid pill distribut
time frame although opioid pill count
purdu rel lower manufactur
list prosecut appear aggress target
purdu opioid drug brand heavili
market drug manufactur spend signific dollar
market brand drug like crux civil
case unlik brand drug gener significantli
cheaper formul sold base price
activ market result case gener
manufactur produc larger quantiti
like penal heavili peer brand
opioid view
second largest distributor
grow faster peer indic
distributor fourth largest
volum opioid prescript period
billion pill amerisourc distribut partner
walgreen estim second largest opioid
distributor billion pill amerisourc growth
larg driven larger exposur specialti drug
improv sell-through servic walgreen
amerisourcebergen oper hinder
remedi cost compound busi acquir
continu success specialti like
mask drag next five year forecast
cash flow billion
cardin health smallest distributor growth
driven increas specialti mix compani
hinder integr prior acquisit especi
contract manufactur commod medic devic
indic distributor
third largest volum opioid pill billion
model free cash flow billion next sever
year aug compani file prospectu
sec unidentifi mix shelf offer common
prefer debt secur suspect file
pre-empt need fund propos opioid litig
largest distributor continu
challeng canada segment result
anticip compani grow slightli slower
peer compani least leverag forecast
gener largest free cash flow next five year
billion indic
distributor largest volum opioid pill billion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
year
headwind time expens
manag hesit provid color beyond
offer posit color track cost save
partnership initi longer term compani continu
make invest transform store destin
improv digit product offer
result ahead expect help
stronger prescript volum acceler share
repurchas despit higher volum gross margin
slightli shi expect due increas mix
shift toward central pharmaci brand drug
gener lower margin overal reimburs appear
stabil compani benefit better
perform value-bas contract expans
narrow network result reinforc thesi
compani abl leverag scale foster benefici
partnership better util store abat commod
price pressur off-set neg reimburs trend
maintain fair valu estim share
nearli improv oper trend
third quarter revenu grew year year
constant currenc basi billion
retail pharmaci sale increas intern
sale declin larg due continu currenc
headwind basi point due compani store
point adjust prescript increas
compar same-stor sale prescript
grew respect front-end sale
decreas declin same-stor basi
larg due store optim strong central fill growth
increas brand drug volum neg
impact gross margin sale
despit lower gross margin shift mix
increas volum initi progress compani cost
initi acceler share buy back enabl
walgreen report normal ep better
expect manag continu
repurchas share drive share count year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end august
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
